| Title: |
Prospective, multicenter European study of the GORE flow reversal system for providing neuroprotection during carotid artery stenting |
| Authors: |
Nikas, Dimitrios; Reith, Wolfgang; Schmidt, Andrej; Duda, Stephan; Mathias, Klaus; Cremonesi, Alberto; Dill, Harold; Formgren, Johan; Pieniazek, Piotr; Musialek, Piotr; Hornung, Marius; Sievert, Horst; Reimers, Bernhard |
| Source: |
Catheterization and Cardiovascular Interventions ; volume 80, issue 7, page 1060-1068 ; ISSN 1522-1946 1522-726X |
| Publisher Information: |
Wiley |
| Publication Year: |
2012 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Background Embolic protection devices (EPDs) are used to provide protection against brain embolization during carotid artery stenting (CAS) to treat carotid artery stenosis, but the optimal type of EPD has not been determined. Distally positioned filters are commonly used but do not provide protection during crossing of the lesion. This prospective, multicenter study investigated a proximally placed device (GORE Flow Reversal System) that reverses blood flow in the internal carotid artery during CAS, thereby directing emboli away from the brain. Methods Outcomes in 122 patients (28% symptomatic), who underwent CAS using the flow reversal system were assessed (intention‐to‐treat analysis). The primary endpoint was a major adverse event (MAE; defined as death or stroke) within 30 days of CAS. The secondary endpoint was a myocardial infarction (MI) or nonstroke‐related neurologic event within 30 days. Results The flow reversal system could not be used in one patient because of severe vessel tortuosity and in two patients (1.6%) because of intolerance. The 30‐day MAE rate and the secondary endpoint rate were each 1.6%. No patient in the series died or had an MI within 30 days. No patient who was symptomatic before CAS had an MAE. One symptomatic and one asymptomatic patient had a transient ischemic attack. Conclusions Use of the GORE Flow Reversal System during CAS had a high rate of technical success and low 30‐day rates of adverse neurologic and cardiac events. © 2012 Wiley Periodicals, Inc. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1002/ccd.24402 |
| Availability: |
https://doi.org/10.1002/ccd.24402; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fccd.24402; https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.24402 |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.8AC91523 |
| Database: |
BASE |